Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 1,662,162 shares of common stock, par value $0.00001 per share ("Common Stock") held by ADAR1 Partners, LP and (ii) 274,961 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC as of June 30,2025. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 35,850,037 shares of Common Stock of BioAge Labs, Inc. (the "Issuer") outstanding as of June 30, 2025, reported in the Issuer's 10-Q, filed with the SEC on August 6, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 1,662,162 shares of common stock, par value $0.00001 per share ("Common Stock") held by ADAR1 Partners, LP and (ii) 274,961 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC as of June 30, 2025. As the manager of ADAR1 Capital Management, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 35,850,037 shares of Common Stock of BioAge Labs, Inc. (the "Issuer") outstanding as of June 30, 2025 reported in the Issuer's 10-Q, filed with the SEC on August 6, 2025.


SCHEDULE 13G



 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:08/14/2025
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:08/14/2025
Exhibit Information

Exhibit A: Joint Filing Agreement